The HIV-1 viral accessory protein Vif prevents the encapsidation of the antiviral cellular cytidine deaminases APOBEC3F and APOBEC3G by inducing their proteasomal degradation. In the absence of Vif, APOBEC3G is encapsidated and blocks virus replication by deaminating cytosines of the viral cDNA. APOBEC3G encapsidation has been recently shown to depend on the viral nucleocapsid protein; however, the role of RNA remains unclear. Using APOBEC3G deletion and point mutants, we mapped the encapsidation determinant to the Zn 2+ coordination residues of the N-terminal catalytic domain (CD1). Notably, these residues were also required for RNA binding. Mutations in the two aromatic residues of CD1 but not CD2, which are conserved in cytidine deaminase core domains and are required for RNA binding, prevented encapsidation into HIV-1, HTLV-I and MLV. The Zn 2+ coordination residues of the C-terminal catalytic domain (CD2) were not required for encapsidation but were essential for cytidine deaminase activity and the antiviral effect. These findings suggest a model in which CD1 mediates encapsidation and RNA binding while CD2 mediates cytidine deaminase activity. Interestingly, HTLV-I was relatively resistant to the antiviral effects of encapsidated APOBEC3G. D
Introduction
Lentiviruses, with the exception of equine infectious anemia virus, require the accessory protein Vif to replicate in primary CD4 + T cells and monocytes. Vif has been shown to relieve the inhibitory activity of cellular cytidine deaminases of the APOBEC3 family (Sheehy et al., 2002) . APOBEC3F and APOBEC3G become encapsidated in Dvif HIV-1 virions, causing CYU deamination of the viral DNA that is synthesized in the subsequent round of replication (Bishop et al., 2004; Harris et al., 2003; Lecossier et al., 2003; Liddament et al., 2004; Mangeat et al., 2003; Mariani et al., 2003; Wiegand et al., 2004; Zhang et al., 2003; Zheng et al., 2004) . The uracil-containing viral cDNA molecules are degraded by cellular DNA repair enzymes prior to integration. In cells infected with wild-type HIV-1, Vif binds to APOBEC3G, inducing its rapid ubiquitination and degradation before it can become encapsidated (Mehle et al., 2004; Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003) . Vif-induced degradation of APOBEC3G is mediated by an E3 ubiquitin ligase of the ECS type that is composed of elongins B and C, Cul5 and Rbx1 to which Vif binds (Yu et al., 2003) .
APOBEC3 molecules are conserved in primate and rodent genomes and are active against HIV-1 when expressed in human cells (Mariani et al., 2003) . However, the interaction of Vif with APOBEC3G is species-specific (Mariani et al., 2003) . The mouse genome contains a single APOBEC3 gene that is about~30% identical to the human orthologue. Mouse APOBEC3 blocked HIV-1 regardless of the presence of Vif. Similarly, African green monkey (AGM) and rhesus macaque APOBEC3Gs were active against Dvif and wild-type HIV-1 (Mariani et al., 2003) . The species-specificity resulted from the inability of Vif to bind noncognate APOBEC3G, which was determined by a single amino acid of APOBEC3G at position 128 Mangeat et al., 2004; Schrofelbauer et al., 2004; .
In humans, the APOBEC family of cytidine deaminases includes APOBEC1, APOBEC2, APOBEC3A-G and the activation induced deaminase (AID) (Harris et al., 2002; Jarmuz et al., 2002) . APOBEC1 is an RNA editing enzyme which in a complex with APOBEC complementing factor deaminates a single cytosine of apolipoprotein B mRNA to introduce a termination codon. APOBEC1 also has nonspecific cytosine deaminase activity on DNA (Harris et al., 2002) . AID is required for somatic hypermutation and class switch recombination Muto et al., 2000; Revy et al., 2000) in B lymphocytes (Jarmuz et al., 2002) .
APOBEC family members contain a domain structure characteristic of cytidine deaminases (Jarmuz et al., 2002) . A short a-helical domain is followed by a catalytic domain (CD), a short linker peptide and a pseudocatalytic domain (PCD). In APOBEC3B, APOBEC3F and APOBEC3G, the entire unit is duplicated to form the domain structure helix1-CD1-linker1-PCD1-helix2-CD2-linker2-PCD2. Each catalytic domain contains the conserved motif H-X-E-(X) 27-28 -P-C-X-X-C in which the His and Cys residues coordinate Zn 2+ and the Glu serves as a proton shuttle in the deamination reaction (Betts et al., 1994; Wedekind et al., 2003) . CD1 and CD2 contain conserved aromatic residues located between the H-X-E and P-C-X-X-C residues (Phe70 and Tyr91 in CD1 and Phe262 and Phe282 in CD2) that in APOBEC1 are required for RNA binding (Navaratnam et al., 1995) .
The mechanism by which APOBEC3G is encapsidated in HIV-1 virions has been the subject of several recent reports. There is general agreement that encapsidation is dependent upon the nucleocapsid (NC) domain of Gag (Alce and Popik, 2004; Cen et al., 2004; Douaisi et al., 2004; Luo et al., 2004; Schafer et al., 2004; Zennou et al., 2004) . Interaction between APOBEC3G and NC has been shown by GST-pull down assays (Alce and Popik, 2004; Douaisi et al., 2004) , coimmunoprecipitation experiments (Cen et al., 2004; Luo et al., 2004; Zennou et al., 2004) and also in a binding assay using in vitro translated proteins (Schafer et al., 2004) . NC also serves to capture the viral genomic RNA and thus it is possible that the RNA can contribute to APOBEC3G encapsidation. Evidence showing that purified recombinant APOBEC3G and NC directly interact (Alce and Popik, 2004) and that RNase A treatment does not alter the ability to coimmunoprecipitate Gag and APOBEC3G (Cen et al., 2004; Douaisi et al., 2004) would suggest no requirement for RNA. However, others have found that the interaction was sensitive to ribonucleases (Schafer et al., 2004; Svarovskaia et al., 2004; Zennou et al., 2004) .
Here, we further defined the determinants of APO-BEC3G that are required for encapsidation. Our results show that the critical domain of APOBEC3G required for encapsidation mapped to the conserved Zn 2+ coordinating residues of the N-terminal catalytic domain (CD1) and that these residues are required for RNA binding. Mutational analyses showed that CD1 was important for RNA binding, homodimerization and encapsidation, while CD2 was the catalytically active site. The findings suggest that APO-BEC3G CD1 serves as the encapsidation and dimerization domain and CD2 catalyzes deamination of the reverse transcripts.
Results

Virions deleted for NC encapsidate a significant amount of APOBEC3G
Several reports have demonstrated the dependence of APOBEC3G encapsidation on the Gag nucleocapsid (NC) (Alce and Popik, 2004; Cen et al., 2004; Douaisi et al., 2004; Luo et al., 2004; Schafer et al., 2004; Svarovskaia et al., 2004; Zennou et al., 2004) . However, in our analysis of a minimal Gag that was deleted for NC, called Zwt, we found a small but consistent amount of APOBEC3G ( Fig. 1A ). In this construct, NC is replaced by the leucine zipper domain of the yeast transcription factor GCN4 and lacks p1 and p6 (Accola et al., 2000) . To determine whether this might have been due to overexpression of APOBEC3G, we tested its encapsidation over a wide range of expression levels, comparing to full-length construct, Pr55 (Fig. 1A ). Because Zwt expressed Vif, the APOBEC3G with a D128K mutation which prevents the interaction with HIV-1 Vif was used (Schrofelbauer et al., 2004) . Zwt particles consistently encapsidated about 10-fold less APOBEC3G than Pr55 over the range of concentrations. The amount of APOBEC3G synthesized in the cells was proportional to the amount of plasmid in the transfection. Thus, in agreement with the findings of others (Alce and Popik, 2004; Cen et al., 2004; Douaisi et al., 2004; Luo et al., 2004; Schafer et al., 2004; Zennou et al., 2004) , NC was an important determinant of APOBEC3G encapsidation, but a significant amount of APOBEC3G encapsidation occurred even in the absence of NC. Quantitation of the viral RNA content of the Zwt virions by dot blot, showed that even without NC a small amount of viral RNA had been packaged (Fig. 1A, bottom) . These results suggested that APOBEC3G could be encapsidated independent of NC, perhaps as a result of binding to RNA.
The viral RNA is not required
To determine whether this could have been due to an association with the viral RNA, we analyzed APO-BEC3G incorporation into virus particles that lacked viral genomic RNA. We generated VLPs using a CMV-driven Gag-Pol expression vector pMDL-RRE that lacked the packaging sequences upstream the gag. These VLPs contained wild-type amounts of APO-BEC3G ( Fig. 1B , middle) but contained no detectable viral RNA (Fig. 1B, bottom) . The strength of the signal in the DVif particles as compared to the Gag-Pol particles (Fig. 1B , bottom) clearly showed that APO-BEC3G encapsidation is not dependent on the viral genomic RNA, which is consistent with previous findings (Cen et al., 2004; Svarovskaia et al., 2004; Zennou et al., 2004) .
APOBEC3G encapsidation requires the Zn 2+ coordination residues of CD1
The feature of APOBEC family proteins that allows their encapsidation into retroviral virions is not known. To map the domains of APOBEC3G required for encapsidation, we generated a panel of APOBEC3G deletion mutants ( Fig. 2A ) and tested their encapsidation into DVif HIV-1 particles. With the exception of the N-terminal fragment, the deleted proteins were stably expressed in transfected cells. For several of the deletion mutants additional bands were seen on the blots which might correspond to products of degradation or post-translational modifications ( Fig. 2B ; the bands corresponding to the expected sizes are indicated with an asterisk). It is of note that several species of different mobility were detected as well for APOBEC3G wild type. Importantly, none of the deletion mutants was efficiently encapsidated (Fig. 2B ). Deletion of as little as the first 54 amino acids prevented encapsidation.
To further define critical amino acid residues for encapsidation, point mutants of the conserved residues of the zinc finger motifs in CD1 and CD2 were tested (Fig. 3A) . Fig. 1 . Encapsidation of significant amounts of APOBEC3G into NC-deleted virions and lack of requirement for viral RNA. (A) Virions composed of fulllength Gag Pr55 or deleted Gag lacking NC, p1 and p6 (diagrammed above) were generated in the presence of decreasing amounts of HA tagged APOBEC3G expression vector. The amount of pcAPOBEC3G-HA transfected is indicated above in Ag. APOBEC3G content of the virions and transfected cells was analyzed on immunoblots probed with anti-HA Mab. The blots were reprobed with anti-p24 MAb to determine the amount of virions. (B) Virions lacking viral genomic RNA were tested for APOBEC3G encapsidation using the gag-pol expression vector pMDL-RRE (diagrammed above). For this experiment, the amount of particles was normalized by p24. Arrows on the left indicate the position of APOBEC3G, CA, Pr55 and Zwt. Dot blot measurement of the viral RNA content of the virions is shown at the bottom. Controls are included for transfection of a NL4-3 with a stop codon in Gag (Gag À ) and lacking viral DNA (empty). PhosphoImager quantitation of the band intensities is shown below.
Mutation of the His65/Cys97/Cys100 box and the catalytic Glu67 in CD1 (Zn1) to Ala prevented encapsidation ( Fig. 3B ). Mutation of the analogous amino acids in CD2 (Zn2), in contrast, had no significant effect. The double mutant (Zn1/2) was also not encapsidated ( Fig. 3B ). Thus, the conserved residues of CD1 but not CD2 were critical for encapsidation. The mutated proteins were stably expressed although those with mutations in CD1 were expressed with a modest decrease in steadystate level.
Mutation of the Zn 2+ coordinating Cys residues, Cys97 and Cys100, of CD1 to Ala (1CCAA) was sufficient to substantially reduce encapsidation (Fig. 3C ). The analogous mutations in CD2 of Cys288 and Cys291 to Ala (2CCAA) had no significant effect. Mutation of the Zn 2+ coordination Cys residues in CD1 to Ser, a more conservative change, also substantially reduced encapsidation ( Fig. 3C ).
Additional mutants were tested in which two conserved aromatic residues within the core motif that have been shown to mediate RNA binding (Navaratnam et al., 1995) were changed to Ala. Mutations F70A/Y91A in CD1 (1FYAA) prevented encapsidation (Fig. 3C ). The analogous change in CD2 of F262A/F282A (2FFAA) also decreased encapsidation, although its effect was not as pronounced as in the 1FYAA mutant ( Fig. 3C ). These findings suggested that the Zn 2+ coordinating residues and the conserved residues involved in RNA binding in CD1 were critical for APOBEC3G encapsidation.
To further test the role of the conserved residues, single point mutants were analyzed. Single mutations in the CD1 Zn 2+ coordination residues H65A, C97A and C100A all prevented or reduced encapsidation, while mutation of the catalytic Glu67 had no significant effect ( Fig. 4A) . Similarly, mutation of the catalytic residue Glu259 had no major effect on encapsidation ( Fig. 4A ). All of the proteins were stably expressed although, changes in the Zn 2+ coordination residues caused a 2-to 4-fold decrease in steady-state level suggesting that these residues also play a structural role in the enzyme. Taken together, these findings suggested the Zn 2+ coordination residues of CD1 are critical for encapsidation.
The catalytic residue Glu259 in CD2 is required for antiviral activity
The contribution of the conserved amino acids of the zinc finger motifs in CD1 and CD2 to the antiviral activity of APOBEC3G was determined by single-cycle luciferase reporter virus assay. The CD1 mutants Zn1, Zn1/2, 1CCAA, 1FYAA and the CD2 mutant 2FFAA which were poorly encapsidated had no effect on infectivity (Fig. 4B , top). The CD2 mutants Zn2 and 2CCAA also had no effect on infectivity, despite of being efficiently encapsidated ( Fig. 4B, top) . Single amino acid mutations of the Zn 2+ coordination residues His65, Cys97 and Cys100 of CD1 had no major effect on infectivity (Fig. 4B, bottom) . Full-length and mutant APOBEC3Gs were detected using an anti-HA antibody. Viral Gag proteins were detected by an anti-p24 antibody. Comparable amounts of virus particles were used, as indicated by immunoblotting with the anti-p24 MAb. Quantitative analysis, calculated as the relative ratio of APOBEC3G in virions as compared to cell lysates and normalized for the ratio obtained with APOBEC3G wild-type, is shown below. Importantly, mutation of the CD1 catalytic residue Glu67 did not reduce antiviral activity. In contrast, mutation of the analogous CD2 amino acid, Glu259, largely diminished the antiviral effect (Fig. 4B, bottom) . These findings suggested that the catalytic activity that deaminates the viral genome is primarily mediated by CD2.
Cytidine deaminase activity resides in CD2
To directly test the relative contributions of the active sites, we measured cytidine deaminase activity of the mutant proteins. The mutant proteins were encapsidated in virions and then released by detergent solubilization. Cytidine deaminase activity was tested using a 5V-end labeled oligonucleotide substrate that contained a consensus CCCA target site (Yu et al., 2004b) . The molecules were cleaved at the deaminated dU by treatment with uracil DNA glycosylase and NaOH and detected by autoradiography. The 1CCAA mutant was partially active while the 2CCAA was inactive (Fig. 5 ). The partial activity of 1CCAA should be considered in light of its inefficient encapsidation. This mutant may be almost fully active on a molar basis. Importantly, mutation of the CD1 catalytic amino acid Glu67 resulted in a fully active enzyme, while mutation of the analogous CD2 amino acid in Glu259 inactivated the enzyme. Thus, CD2 appeared to mediate deamination of DNA.
RNA binding requires the Zn 2+ coordination residues of CD1 It has been described that APOBEC3G is able to bind RNA in vitro (Jarmuz et al., 2002; Yu et al., 2004b) . To determine the relative contribution of the Zn 2+ coordination residues of CD1 and CD2 to the ability of APOBEC3G to bind RNA, recombinant proteins with mutations in these residues were tested for RNA binding by EMSA (Yu et al., 2004b) . Wild-type, 1CCAA and 2CCAA mutant APOBEC3Gs were purified from E. coli as glutathione S-transferase (GST) fusion proteins. In Fig. 3 . The Zn 2+ coordination residues of CD1 are required for efficient encapsidation. Virions were generated with Dvif NL4-3 (Dvif) and the mutated APOBEC3G-HA expression vector indicated above each lane. (A) Diagram showing the altered conserved residues on each mutant. (B) APOBEC3G mutated in the active site motif of CD1 (Zn1), CD2 (Zn2) or CD1 and CD2 (Zn1/2). APOBEC3G content was analyzed on immunoblots probed with anti-HA MAb. The position of APOBEC3G and CA is indicated by arrows on the left. (C) APOBEC3G mutated in the Zn 2+ coordination residues and aromatic conserved RNA binding residues of CD1 and CD2. Quantitative analysis, as performed in Fig. 1 , is shown for panels B and C. addition, APOBEC3A was used as a control. The two cysteines in the active site of APOBEC3A are separated by four amino acid residues and therefore is postulated not to coordinate zinc (Jarmuz et al., 2002) . The proteins were tested for binding to oligoribonucleotides that lacked C and U (no C/U) that contained C (C-rich) or to deoxyoligonucleotides lacking C (no C) or containing C (C-rich) (Fig. 6 ). Wild-type APOBEC3G bound to ribooligonucleotides regardless of its C-content and bound to the deoxyoligonucleotides that contained C. Thus, the enzyme bound nonspecifically to RNA but bound to DNA that is targeted by for deamination. Control GST and GST-APOBEC3A did not bind to nucleic acid. Alteration of the Zn 2+ coordination residues in CD1 dramatically reduced the ability of the protein to bind RNA and DNA (Fig. 6 ). Alteration of CD2 had no effect on binding of oligoribonucleotides that contained C (C-rich) or deoxyoligonucleotides that contained C. This mutant may have a reduced ability to bind oligoribonucleotides that lacked C and U although this difference could be within experimental variability (no C/U) ( Fig. 6 ). We concluded that nucleic acid binding is primarily mediated by CD1.
CD1 Zn 2+ coordination residues are required for APOBEC3G dimerization APOBEC1, APOBEC2, APOBEC3B and APOBEC3G are homodimers (Jarmuz et al., 2002; Lau et al., 1994) . To determine which domains of APOBEC3G are required for Fig. 4 . Mutations in the conserved Zn 2+ coordinating motif of CD2 abrogate antiviral activity. (A) Immunoblot analysis of encapsidation of APOBEC3G mutants with individual amino acid residues in the conserved Zn 2+ binding motif changed to Ala in CD1 (H65A, E67A, C97A and C100A) and CD2 (E259A). Quantitative analysis, as performed in Fig. 1 , is shown below. (B) Antiviral activity of the indicated mutated APOBEC3Gs was determined by single-cycle luciferase reporter virus assay. Negative controls include infections using supernatant from 293T cells transfected with pcDNA alone or pcAPOBEC3G alone. Virions containing wild-type or the indicated mutant APOBEC3G were produced in 293T cells, pelleted and solubilized in detergent-containing buffer to release the encapsidated enzyme. The lysates were incubated with 5V-( 32 P) labeled oligonucleotide and then cleaved at sites of CYU deamination by treatment with UDG. As controls, virions were produced in the absence of APOBEC3G (lane 1) or without viral plasmid (lane 2). An oligonucleotide containing a dU in place of the target dC served as a marker for the cleaved product (lane 8).
dimerization, the ability of 1CCAA and 2CCAA to dimerize with wild-type APOBEC3G was tested (Fig. 7) . 293T cells were cotransfected with equal amounts of mutated HAtagged APOBEC3G and wild-type myc-tagged APO-BEC3G expression vector. Dimerization was assessed by coimmunoprecipitation followed by immunoblot analysis. Wild-type APOBEC3G-myc coimmunoprecipitated with wild-type APOBEC3G-HA. In this analysis, the 2CCAA protein dimerized but 1CCAA did not (Fig. 7) . Thus, the Zn 2+ coordination residues in CD1 but not in CD2 are required for dimerization of APOBEC3G.
CD1 mediates encapsidation of APOBEC3G into human T cell leukemia virus type 1 (HTLV-I) and murine leukemia virus (MuLV)
HTLV-I and HTLV-II do not encode Vif yet both replicate in T cells. To determine whether HTLV-I encapsidated APOBEC3G and whether this affected its infectivity, HTLV-I virions were produced in 293T using an HTLV-I packaging construct and a luciferase encoding transfer vector (Derse et al., 2001) . The virions were produced in cells cotransfected with pc-APOBEC3G-HA and APO-BEC3G content was determined by immunoblot analysis. Encapsidated APOBEC3G was readily detected (Fig. 8A) . The analysis did not permit absolute quantitation, but the intensity of the APOBEC3G and CA bands were similar to those found for HIV-1 virions. Intracellular levels of APOBEC3G were not affected by the presence of the HTLV-I proteins in the transfected cells, suggesting that the virus did not induce APOBEC3G degradation. The effect of APOBEC3G on virion infectivity was determined by titrating the amount of pcAPOBEC3G-HA plasmid and including VSV-G vector to generate infectious pseudotypes. The virus was then used to infect fresh 293T cells (Fig. 8B) . For comparison, Dvif HIV-1 virions were tested in parallel. At the highest amount of pcAPOBEC3G (2 Ag), infectivity was reduced about 2-fold. In contrast, the infectivity of Dvif HIV-1 was reduced about 30-fold. With 1 Ag of pcAPO-BEC3G HTLV-I infectivity was not significantly reduced ( Fig. 8B) . Thus, HTLV-I, like MuLV (Mariani et al., 2003) , appeared to be relatively resistant to APOBEC3G.
To determine whether APOBEC3G was encapsidated into divergent retroviruses by a mechanism similar to that Fig. 7 . APOBEC3G dimerization requires CD1 Zn 2+ coordination residues. 293T cells were cotransfected with HA or myc-tagged APOBEC3G expression vector. HA tagged APOBEC3G was wild-type, mutated in CD1 (1CCAA) or CD2 (2CCAA) Zn 2+ coordination Cys residues or was deleted for CD1 (Cfragment that includes aa 163 to 384 of APOBEC3G). Cell lysates were prepared and immunoprecipitated with anti-HA Mab. The immunoprecipitates were analyzed on immunoblots probed with anti-myc MAb. All of the proteins were expressed at similar levels (not shown). As controls, the cells were transfected with empty vector (pcDNA) or APOBEC3G-myc alone (APO3G-myc). Fig. 6 . RNA binding by APOBEC3G is primarily determined by CD1 Zn 2+ coordination residues. APOBEC3A and APOBEC3G wild-type and the mutants 1CCAA and 2CCAA were produced in E. coli as GST fusion proteins and purified by affinity chromatography. 5V-end 33 P labeled oligoribonucleotide was incubated with the indicated APOBEC3G proteins. Two RNA oligonucleotides were used, one lacked C and U (no C/U) and one was enriched for C (C-rich) and two DNA oligonucleotides were used, one lacking C (no C) and one enriched for C (C-rich). The complex was separated on native PAGE and exposed to X-ray film. A low mobility nonspecific band is present for all proteins incubated with the no C/U oligoribonucleotide.
for HIV-1, encapsidation of mutated APOBEC3Gs into MuLV and HTLV-I was tested. As for HIV-1, the 1FYAA mutant in which aromatic residues of CD1 were mutated was not encapsidated into MuLV or HTLV-I. In contrast, the 2FFAA mutant was encapsidated in both viruses (Fig. 9 ). The 2FFAA mutant was encapsidated at somewhat lower efficiency into HTLV-I, which is consistent with the results obtained for HIV-1 (compared to Fig. 3C ). Overall, APOBEC3G was encapsidated into MuLV and HTLV-I by a mechanism that was similar to HIV-1.
Discussion
The findings presented here suggest a model for APOBEC3G function in which domain 1 directs encapsidation and domain 2 serves as the catalytic site. The antiviral activity of APOBEC3G requires the function of both domains. In support of this model, domain 1 Zn 2+ coordination amino acids were required for encapsidation, while domain 2 Zn 2+ coordination amino acids were dispensable. A stable C-terminal fragment of APOBEC3G was not encapsidated. The active site of cytidine deaminase domains contains an essential Glu residue. Domain 1 Glu67 was dispensable for antiviral activity while domain 2 Glu259 was required. It should be noted that E259A retained weak antiviral activity, although no signal was detected in the cytidine deaminase activity assay. The residual antiviral activity could be taken to indicate an antiviral activity separate from the deaminase activity (Shindo et al., 2003; Turelli et al., 2004) , but it is more likely that the protein retains weak deaminase activity that is beyond the limit of sensivity of the in vitro assay. Neither of the catalytic Glu residues was required for encapsidation. RNA binding by the APOBEC3G and homodimerization were mediated by the domain 1 Zn 2+ coordination residues. It may be that a two-domain structure is needed for the antiviral effect of APOBEC3 proteins in general, as the two domain proteins APOBEC3B, APOBEC3F and APO-BEC3G are active while APOBEC3A which consists of a single domain is not (Bishop et al., 2004; Yu et al., 2004a) .
The mechanism of APOBEC3G encapsidation has been addressed in several recent reports. There is general agreement that NC is an important determinant of APOBEC3G encapsidation (Alce and Popik, 2004; Cen et al., 2004; Douaisi et al., 2004; Luo et al., 2004; Schafer et al., 2004; Zennou et al., 2004) . However, because NC mediates viral RNA packaging (Aldovini and Young, 1990; Gorelick et al., 1990) , it has been difficult to distinguish whether the requirement stems from direct binding of APOBEC3G to NC or to the viral RNA. Evidence that binding to NC was sufficient was suggested by the finding that purified recombinant APOBEC3G and NC directly interact (Alce and Popik, 2004) and that RNase A treatment does not interfere with the ability to coimmunoprecipitate Gag and APOBEC3G from transfected cells (Cen et al., 2004; Douaisi et al., 2004) . However, others have found that the interaction was sensitive to ribonucleases (Schafer et al., 2004; Svarovskaia et al., 2004; Zennou et al., 2004) . Viral RNA packaging-deficient viruses incorporated normal amounts of APOBEC3G, as shown here and by others previously (Cen et al., 2004; Luo et al., 2004; Schafer et al., 2004; Svarovskaia et al., 2004; Zennou et al., 2004) . However, such virions are likely to package cellular RNA (Aronoff and Linial, 1991; Berkowitz et al., 1996) and these could substitute for the viral RNA in facilitating APO-BEC3G encapsidation. Although it is clear that viral RNA is not required, our findings support a role for RNA in APOBEC3G encapsidation. First, virions deleted for NC consistently packaged about 10% the wild-type amount of APOBEC3G, demonstrating that the virus has another determinant for APOBEC3G encapsidation besides NC. Second, mutations in APOBEC3G that affected RNA binding blocked encapsidation. The Zn 2+ coordination residues of domain 1 which were required for RNA binding were also required for APOBEC3G encapsidation. In addition, the conserved aromatic residues F70 and Y91 of CD1, which in APOBEC1 are required for RNA binding (Navaratnam et al., 1995) were also required for APO-BEC3G encapsidation in HIV-1, MLV and HTLV-I.
Our findings differed somewhat from those of Cen et al., and Luo et al., who mapped an encapsidation determinant to the N-terminal linker domain of APOBEC3G (Cen et al., 2004; Luo et al., 2004) . In those studies, the proteins were encapsidated into Gag VLPs and not into native HIV-1 virions as in our study, although whether this could have influenced the findings is not clear. Consistent with our results, Li et al., found that a D1-67 APOBEC3G deletion mutant, that lacks the conserved His of the first conserved Zn 2+ finger, was not encapsidated into DVif HIV-1 virions (Li et al., 2004) .
The ability of NC-deleted virions to encapsidate a small but significant amount of APOBEC3G argues against a simple protein-protein interaction between APOBEC3G and NC. Moreover, the broad species-specificity of the encapsidation also argues against this. APOBEC3G is efficiently encapsidated by divergent retroviruses including MuLV and HTLV-1 (Harris et al., 2003; Mangeat et al., 2003; Mariani et al., 2003) , the NC proteins of which are highly divergent. Moreover, mouse APOBEC3, which has only~30% homology to the human protein is also efficiently encapsidated in HIV-1 (Mariani et al., 2003) . In addition, it seems likely that if binding to NC was the sole determinant of APOBEC3G encapsidation, the virus would have escaped simply by altering the NC amino acid sequence. A role for RNA in APOBEC3G encapsidation would provide a mechanism from which the virus could not easily escape. A role for RNA, however, presents the paradox of how APOBEC3G is encapsidated into packaging site mutant virions. Such virions are thought to package cellular RNA yet it does not seem likely that APOBEC3G molecules could coat much of the cellular mRNA. We therefore speculate that APOBEC3G encapsidation is mediated by a complex of NC with RNA in which APOBEC3G binds to a composite site formed by the complex of NC with RNA.
Lastly, we found that APOBEC3G could be encapsidated in HTLV-I virions yet did not reduce its infectivity. HTLV-I replicates in T cells yet does not encode a Vif-like protein and did not appear to induce APOBEC3G degradation, arguing that it does not encode a Vif analog. This finding raises the question of how viruses such as HTLV-1 and MuLV that lack Vif are able to replicate in the presence of APOBEC3G. One possibility is that their reverse transcription complex is not accessible to the encapsidated deaminase. This further poses the question of why HIV-1 was not able to become resistant to deamination by a similar mechanism but instead used the alternative strategy of developing a novel gene as a means of escaping this cellular antiviral activity.
Materials and Methods
APOBEC3G expression vectors
HA and myc tagged human APOBEC3G expression vectors pcAPOBEC3G-HA (Mariani et al., 2003) and pcAPOBEC3G-myc were constructed by cloning a human APOBEC3G cDNA into the EcoRI and XhoI sites of pcDNA3.1(+) (Invitrogen) using primers that encoded the corresponding C-terminal epitope tag. APOBEC3G mutants were generated by overlapping PCR using pcAPOBEC3G-HA as template. 5V and 3V fragments were amplified separately with a primer specific for the overlap region and a 5V external primer 5V-Apo3G.EcoRI (5V-TAG ATC GAA TTC ATG AAG CCT CAC TTC AGA AAC ACA G) or a 3V primer 3V-Apo3G.HA.Xho (5V-ATT GAA TCT CGA GTC AAG CGT AAT CTG GAA CAT CGT ATG GAT AGT TTT CCT GAT TCT GGA GAA TGG CCC GCA G). The 5V and 3V fragments were mixed and amplified with the two external primers. The amplicon was cleaved with EcoRI and XhoI and cloned into pcDNA3.1(+). All plasmids were confirmed by sequencing. pcAPOBEC3G D128K has been previously described (Schrofelbauer et al., 2004) .
HIV-1 and HTLV-I proviral plasmids
Single cycle Dvif HIV-1 (pNL4-3 E À R À Dvif) provirus and Dvif HIV-1 luciferase reporter virus (pNL-Luc-E À R À Dvif) were previously described (Schrofelbauer et al., 2004) . Pr55 encodes a full-length HIV-1 genome with a point mutation that inactivates protease (Accola et al., 2000) . Zwt mutant provirus does not contain p1, p6 and NC was replaced with a yeast leucine zipper domain (Accola et al., 2000) . pMDLg/p is a CMV-driven expression plasmid that contains only the gag and pol coding sequences from HIV-1 (Dull et al., 1998) . HTLV-I virions were generated with the HTLV-I packaging plasmid, pCMVHT-Denv and transfer vector pHTC-luc (Derse et al., 2001) . MLV virions were generated with Gag/Pol expression vector pHIT-60 (Soneoka et al., 1995) .
Production of recombinant viruses and detection of encapsidated APOBEC3G
APOBEC3G encapsidation into HIV-1, HTLV-I or MLV virions was determined as previously described (Mariani et al., 2003) . 293T cells were maintained in Dulbecco's modified essential medium supplemented with 10% fetal calf serum and antibiotics. Briefly, 293T cells were seeded at 5 Â 10 5 per well in 6 well plates. The following day, the cells were cotransfected with 1 Ag each of pcAPOBEC3G-HA and HIV-1, HTLV-I or MLV plasmid using Lipofectamine 2000 (Invitrogen) . Two days later, virus containing supernatants were collected and virions were ultracentrifuged through a 20% sucrose cushion at 150,000 Âg for 1.5 h. The pellets were solubilized in 100 Al of 1% Tritoncontaining buffer and the proteins in 10 Al were separated on 4-12% PAGE. The proteins were then transferred to PDVF membranes and probed with anti-HA MAb 16B12 (Covance) followed by horseradish peroxidase-(HRP) conjugated sheep anti-mouse Ig (Amersham). The membranes were stripped and reprobed with anti-HIV-1 human serum J810 (provided by Dr. Douglas Richman, UCSD), anti-p24 MAb AG3.0, anti-HTLV-1 p19 MAb (Zymed) or anti-MLV p15 goat serum followed by HRP conjugated anti-human, anti-mouse or anti-goat IgG (Amersham) and developed with ECL reagents (Amersham). Bands in Western blots were quantitated by densitometry using FluorChem 8000 (Alpha Innotech Corporation).
Dot blot analysis
Viral genomic RNA content of wild type and recombinant HIV-1 virus was determined by dot blot analysis. Briefly, virion supernatants from transfected 293T cells were treated with 20 Ag/ml of DNaseI, RNase-free (Roche) for 1 h at RT and then the virions were purified by ultracentrifugation through 20% sucrose, resuspended in PBS and normalized by p24. RNA was extracted from equal amounts of p24 (200 ng) using Trizol Reagent (Invitrogen) and then transferred to a nylon membrane using a dot blot apparatus (Schleicher and Schuell). The membrane was prehybridized 1 h at 68 8C in Express-Hyb Hybridization solution (Clontech). Incubation with the radiolabeled probe (10 6 cpm/ml) was for 2 h at 68 8C. As probe we used an EcoRI/XhoI fragment of pNL4-3 (corresponding to nucleotides 5743 to 8887 of pNL4-3) random labeled with a 32 P-dCTP (ICN) using High Prime (Roche). The membrane was washed twice with 2Â SSC-0.05% SDS for 20 min at RT and once with 0.1Â SSC-0.1% SDS for 40 min at 50 8C and analyzed with a PhosphorImager.
APOBEC3G dimerization assay
239T cells were cotransfected in a six well dish with 1 Ag pcAPOBEC3G-HA or its mutated derivatives and 1 Ag pcAPOBEC3G-myc. Two days posttransfection, the cells were lysed in 1.0 ml CHAPS buffer (5 mM CHAPS, 50 mM Tris, pH 8.0, 50 mM NaCl) at 4 8C for 1 h. The lysates were cleared by microcentrifugation for 20 min at 4 8C. Lysates (250 Al) were precleared twice with 50 Al of a 1:1 slurry of protein-A sepharose for 30 min at 4 8C. Anti-HA MAb (1 Ag) was added to 200 Al of precleared lysate and incubated 2 h at 4 8C followed by addition of 30 Al of protein-A sepharose beads. After 1 h, the beads were collected and washed three times in 1 ml of CHAPS buffer followed by two washes in 1 ml of 50 mM Tris, pH 8.0, 50 mM NaCl. The supernatant was removed and 15 Al of 2Â reducing sample buffer (Invitrogen) was added. Samples were heat to 958 for 5 min and then separated on 4-20% SDS-PAGE. The proteins were transferred to PVDF membranes and probed with anti-myc MAb 9E10 (Covance) followed by HRP-conjugated sheep anti-mouse Ig (Amersham). The membranes were developed using ECL Reagent (Amersham).
HIV-1 and HTLV-I luciferase reporter virus assay
VSV-G-pseudotpyed single-cycle HIV-1 and HTLV-I luciferase reporter viruses were generated as previously described (Connor et al., 1995; Derse et al., 2001) . Briefly, 293T cells were cotransfected using Lipofectamine 2000 (Invitrogen) with 1 Ag of HIV-1 or HTLV-I luciferase reporter virus, 1 Ag of wild type or mutant pcAPOBEC3G-HA or pcDNA3.1(+) and 1 Ag of pcVSV-G. For APOBEC3G titrations, the total amount of plasmid was held constant by the addition of pcDNA3.1(+). Viruscontaining supernatant was harvested 2 days posttransfection filtered and the p24 concentration measured. 293T cells (2 Â 10 5 ) seeded the previous day in six-well plates were infected with 300 Al of HIV-1 or 2 ml of HTLV-I containing supernatant in the presence of 8 Ag/ml polybrene (Sigma). After 6 h, medium was removed and replaced with fresh medium. To assay for luciferase activity, cells were harvested 72 h post infection, pelleted and resuspended in 0.1 ml of lysis buffer (1% Triton X-100, 50 mM NaCl, 10 mM Tris-HCl (pH 7.6), 5 mM EDTA). Luciferase assays were performed with 20 Al of cell extract in the Promega luciferase assay system according to the manufacturer's protocol. Data shown are the mean cps +/À the standard error of the triplicates.
APOBEC3G RNA binding assay
Vectors to produce recombinant APOBEC3 proteins were constructed by transferring APOBEC cDNAs to pGEX-6P-3 plasmid (Amersham) in-frame to the GST coding sequence at the EcoRI and XhoI sites. Recombinant GST-APOBEC3G proteins (wild-type, CD1 1CCAA and CD2 2CCAA mutants) and GST-APOBEC3A were produced in E. coli BL21-DE3 induced with 0.5 mM IPTG. Bacteria were pelleted and lysed in PBS containing 10 mM EDTA/5 mM dithiothreitol/1% triton-X100. The proteins were purified by affinity chromatography on glutathione sepharose beads. DNA and RNA oligonucleotides described by Yu et al. (2004b) were 5V-end labeled with 33 P-gATP using T4 polynucleotide kinase and unincorporated nucleotide was removed on G25 spin column. Each protein (2 Ag) was incubated with oligonucleotide (1 Â 10 5 cpm) in binding buffer (10 mM HEPES, 10% glycerol, 100 mM KCl, 10 mM MgCl 2 , 0.1 mM EDTA, 0.5 mM DTT) at 378 for 40 min and then separated by native PAGE on a 4-20% gradient gel. The gel was dried and exposed to Biomax MR (Kodak) film overnight.
Cytidine deaminase assay
Virions were generated by cotransfection of 293T cells with 1:1 ratio of Dvif pNL4-3 and pcAPOBEC3G-HA. Supernatant was harvested 3 days posttransfection, filtered and pelleted through 2 ml of 20% (w/v) sucrose/PBS by ultracentrifugation for 1h at 35,000 RPM in an SW41 rotor. Pelleted virions were lysed in 100 Al buffer containing 50 mM Tris (pH 8.0), 40 mM KCl, 50 mM NaCl, 5 mM EDTA, 10 mM DTT and 0.1% (v/v) triton-X100. Lysates were normalized for p24 concentration. The virus lysate (100 ng p24) was mixed with 1 Â 10 5 cpm of 5V-end labeled oligonucleotide with the sequence 5V-TTT TTT  TTT TTT TTT CCC GTT TTT TTT TTT TTT TTT TTT TT T in deaminase buffer (40 mM Tris, pH 8.0, 40 mM KCl, 50 mM NaCl, 5M EDTA, 10% (v/v) glycerol, 1 mM DTT). After 5 h at 37 8C, the reactions were terminated by heating to 90 8C for 5 min. The oligonucleotide was then treated with uracil DNA glycosylase (UDG) for 30 min at 37 8C in UDG buffer (20 mM Tris, pH 8.0, 1 mM DTT) and cleaved by treatment with 0.15 M NaOH at 37 8C for 30 min. The products were separated on 15% TBE-urea PAGE and detected by autoradiography. A labeled marker oligonucleotide in which the target C was replaced with U was processed in parallel to indicate the position of the cleaved product.
